Newsfeeds - Spark Newswire

1 minute read

Analyst Says Biogen-Eisai’s Alzheimer’s Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity

Today, 4:27 AM

Eisai Co Ltd (OTC:ESALY) and Biogen Inc (NASDAQ:BIIB) said the U.S. Department of Veteran Affairs (VA) would provide coverage of their…

BIIB

1 minute read

Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer’s Treatment

By Vandana Singh

Today, 4:27 AM

The FDA has accepted Eisai Co Ltd (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) supplemental Biologics License Application (sBLA) for Leqembi (lecanemab-irmb) 100 mg/mL injection,…

BIIB

1 minute read

FDA Accepted Eisai-Biogen’s Supplemental Biologics License Application For Leqembi (Lecanemab-IRMB) 100 mg/ml Injection For Intravenous Use, Supporting The Conversion Of The Accelerated Approval Of Leqembi To A Traditional Approval

By Benzinga Newsdesk

Today, 4:27 AM

The LEQEMBI application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023. The FDA is currently planning to hold an Advisory Committee to discuss this application

BIIB

1 minute read

Despite Safety Concerns, Analysts Are Bullish On Biogen’s Second Alzheimer’s Candidate

By Vandana Singh

Today, 4:27 AM

Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD).

BIIB

1 minute read

Open Questions On Safety Lingers After Eisai-Biogen’s Detailed Lecanemab Data For Alzheimer’s

By Vandana Singh

Today, 4:27 AM

According to detailed data, Eisai Limited (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) closely watched trial of an experimental Alzheimer’s drug slowed cognitive decline but…

BIIB

1 minute read

Biogen’s Potential Early Alzheimer’s Treatment Sees Second Death Linked To It, Shares Fall

By Vandana Singh

Today, 4:27 AM

A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that some researchers link to the drug.

BIIB

1 minute read

Roche’s Alzheimer’s Flop Trial Removes One Competitor, But Reimbursement Debate Lingers

By Vandana Singh

Today, 4:27 AM

Earlier today, MorphoSys AG (NASDAQ:MOR) and its partner Roche Holdings AG (OTC:RHHBY) reported disappointing results from gantenerumab studies in mild cognitive impairment (MCI) due…

BIIB

1 minute read

Despite Advancement, Benefits From Alzheimer’s Drugs May Be Limited, Say Researchers

By Vandana Singh

Today, 4:27 AM

Recently, Biogen Inc (NASDAQ:BIIB) and Eisai Co (OTC: ESALY) announced encouraging data from the most-watched Alzheimer’s therapies in the clinic. Lecanemab cleared accumulations…

BIIB

1 minute read

Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate

By Vandana Singh

Today, 4:27 AM

Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).

ESALF